Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2023 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

BDC-1001 program advances in multiple Phase 2 clinical studies in patients with HER2-positive colorectal, gastric, endometrial, and metastatic breast cancer, with recent updated data at ESMO showing...
November 07, 2023 07:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference

REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer,...
October 23, 2023 10:30 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

Updated safety data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose (RP2D)Improved efficacy with one partial response (PR) improving to a complete response (CR), two additional...
October 18, 2023 07:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting

Company to debut preclinical data illustrating how the combination of trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus...
October 17, 2023 07:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

BDC-3042, a novel Dectin-2 agonistic antibody that stimulates the innate immune system, is being evaluated in a Phase 1/2 dose-escalation and expansion study in patients with a broad range of solid...
October 16, 2023 07:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023

REDWOOD CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the...
September 28, 2023 07:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers

BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersThe FDA granted BDC-1001...
September 12, 2023 08:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042

REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
September 05, 2023 16:15 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Participate in September Investor Conferences

REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer,...
August 07, 2023 16:10 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

First patients dosed in the BDC-1001 Phase 2 programBDC-1001 Phase 1 data presented at ASCO 2023 demonstrated favorable safety profile and encouraging efficacy as a monotherapy and in combination with...